Abstract
Objective To establish the a staging system based on scoring of ketamine associated urinary dysfunction (KAUD) and evaluate its diagnosis performance and clinical value. Methods A retrospective analysis of 135 admitted KAUD patients from September 2009 to September 2015 was performed. All patients were classified into three stages according to bladder and upper urinary tract impairment, and treated with subsequent strategy. The behavioral modification and pharmacotherapy was performed in stage I which image investigation was normal. Hydrodistension and intravesical perfusion was used if pharmacotherapy failed in stage II patients who had bladder impairment in image or urodynamics. Augmentation cystoplasty or cystectomy with urinary diversion was optional if aforementioned treatment failed in stage III who had upper urinary tract involvement and abnormal renal function. The voided volume, micturition interval, and nocturnal void frequency as recorded in their 3-day bladder diary, PUF, ICPI and ICSI score after treatment in one month, were compared with their baseline data prior to treatment. Ketamine abusing history, renal and liver function, bladder and upper urinary tract changes, urodynamics and radioisotope renography correlation with stages were analyzed. A scoring system was established and the concordance between the clinical staging and model staging of each patient was compared. Receiver operating characteristic curve was employed to testify the sensitivity and specificity. Results There were 39, 80 and 16 patients included in each stage respectively. After subsequent strategy of treatment, voided volume, micturition interval, and nocturnal void frequency, PUF, ICPI and ICSI were improved significantly. Age (P=0.018), ketamine abusing history (P=0.006), eGFR (P=0.001), ALT (P=0.037), γ-GT (P<0.001), bladder (P=0.013) and ureteral changes (P<0.001), hydronephrosis (P<0.001) and radioisotope renography abnormality (P=0.01) were correlated with clinical stages. In total, 107 cases’ stages based on scoring were accordant with clinical stages (30, 65 and 12 cases in each stage respectively). AUC of the scoring model ROC was 0.922 on cut point between I and II stages and AUC of the scoring model ROC was 0.978 on cut point between II and III stages. Conclusions We presented a scoring staging system of KAUD based on ketamine abusing history, laboratory test results, and imaging findings. It might be helpful to evaluate the progression on bladder and upper urinary tract, and provide a reference for treatment. This staging system based on scoring still needs further validation and improvement. Key words: Ketamine; Urinary system; Clinical stage; Scoring system; Diagnostic value
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have